From the July 2021 issue of HealthCare Business News magazine


A blinded clinical trial comparing the technology to mammography was published in Academic Radiology online in December 2020. The study found that QT scan provided better sensitivity and specificity than mammography, resulting in fewer callbacks.

“We're very happy that women are getting good results from it,” Klock said. “We're hoping women will be our allies.”


The company plans to expand the indications for use and expects to submit for FDA clearance to measure fibroglandular volume in 2021, which can be affected by a woman’s menstrual cycle or hormone therapy.

“For women on hormone therapy to prevent breast cancer, this will allow measurement of how they’re responding,” Klock said.

Siemens Healthineers
Siemens Healthineers has not debuted any new women's health systems or software within the last year. However, the company has been strategizing with its customers to help them cope with the sudden influx of screening examinations following the screening mammography standstill brought on by the pandemic.

For example, the latest software update on MAMMOMAT Revelation has decreased room time, providing a four-view tomosynthesis exam in under six minutes, allowing facilities to provide 10-minute exam slots.

“Our customers were really valuing that coming out of the pandemic,” said Abigail Weldon, director of women’s health at Siemens Healthineers North America.

Automated breast density reading helps radiologists prioritize further diagnostic needs right away.

The company also offers remote installation, training and support.

Volpara
In January, Volpara Health acquired CRA Health, which has an expertise in breast cancer risk and genetics. This best-of-breed breast cancer risk assessment solution was integrated into Volpara’s Patient Hub mammography reporting and patient communication software. The new solution also provides content to help radiologists explain the patient’s breast cancer risk alongside appropriate recommendations, including whether additional imaging or genetics testing is needed according to established guidelines.

“It’s all about personalizing breast care and helping save families from cancer by preventing advanced stage breast cancer,” said Ralph Highnam, chief executive officer of Volpara Health.

Last fall, the company also launched Project Thumb, a new tool that will allow clinicians to embed mammogram images on patients' breast density notification letters with the goal to educate patients to help them make informed decisions about their breast care.

Later this year, the company plans to upgrade its Volpara Analytics platform, which enables technologists to log in and learn about their own acquisition performance and access education on quality imaging techniques.

Back to HCB News

July 2021 Magazine

Read more stories from the July 2021 issue

More Magazine Features

Women's Health Homepage